GenSight Biologics Presents LUMEVOQ® Data at AAO 2024

GenSight Biologics, a company specializing in gene therapies for retinal diseases and central nervous system disorders, will showcase new findings on LUMEVOQ® at the AAO 2024 in Chicago. The event will highlight comparisons between treatments like idebenone and LUMEVOQ® for Leber Hereditary Optic Neuropathy (LHON), as well as real-world experiences and long-term outcomes from bilateral injections.

Notable presentations include a meta-analysis of treatment outcomes for LHON by Dr. Nancy J. Newman and a discussion on the efficacy and safety of LUMEVOQ® in real-life by Dr. Valerie Biousse. Findings from post-mortem analyses and four-year results of bilateral injections will also be shared, providing extensive insights into LUMEVOQ®'s impacts.